Literature DB >> 20032252

Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California.

Jennifer Le1, Mariana Castanheira, David S Burgess, Barbara McKee, Raza Iqbal, Ronald N Jones.   

Abstract

Carbapenems (CARBs) are the primary treatment for infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strains. Production of a serine carbapenemase, KPC, is increasing alarmingly in the United States and is probably contributing to CARB resistance rates. We describe the clinical and molecular characteristics of four infections caused by KPC-3 K. pneumoniae strains.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20032252      PMCID： PMC2815646          DOI： 10.1128/JCM.02397-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis.

Authors:  Rodrigo E Mendes; Katia A Kiyota; Jussimara Monteiro; Mariana Castanheira; Soraya S Andrade; Ana C Gales; Antonio C C Pignatari; Sergio Tufik
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

3.  Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).

Authors:  Mariana Castanheira; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Microb Drug Resist       Date:  2008-09       Impact factor: 3.431

4.  Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission.

Authors:  David Goldfarb; Sarah-Beth Harvey; Kelsi Jessamine; Peter Jessamine; Baldwin Toye; Marc Desjardins
Journal:  J Clin Microbiol       Date:  2009-04-08       Impact factor: 5.948

Review 5.  The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

Authors:  Patrice Nordmann; Gaelle Cuzon; Thierry Naas
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

6.  NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.

Authors:  Alicia I Hidron; Jonathan R Edwards; Jean Patel; Teresa C Horan; Dawn M Sievert; Daniel A Pollock; Scott K Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

7.  Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.

Authors:  Brandon Kitchel; J Kamile Rasheed; Jean B Patel; Arjun Srinivasan; Shiri Navon-Venezia; Yehuda Carmeli; Alma Brolund; Christian G Giske
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

8.  Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.

Authors:  Thierry Naas; Gaelle Cuzon; Maria-Virginia Villegas; Marie-Frédérique Lartigue; John P Quinn; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

9.  Carbapenem-hydrolysing beta-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil.

Authors:  Gisele Peirano; Liliane M Seki; Vera Lúcia Val Passos; Maria Cristina F G Pinto; Lília R Guerra; Marise D Asensi
Journal:  J Antimicrob Chemother       Date:  2008-11-20       Impact factor: 5.790
  9 in total
  5 in total

1.  Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.

Authors:  Rodrigo E Mendes; M R K Alley; Helio S Sader; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

Review 2.  Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.

Authors:  Grace C Lee; David S Burgess
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-12-13       Impact factor: 3.944

3.  Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin.

Authors:  Romney M Humphries; Theodoros Kelesidis; Jennifer Dien Bard; Kevin W Ward; Debika Bhattacharya; Michael A Lewinski
Journal:  J Med Microbiol       Date:  2010-08-05       Impact factor: 3.196

4.  In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae.

Authors:  Jennifer Le; Barbara McKee; Warunee Srisupha-Olarn; David S Burgess
Journal:  J Clin Med Res       Date:  2011-05-19

5.  Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae.

Authors:  Grace C Lee; David S Burgess
Journal:  J Clin Med Res       Date:  2013-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.